journal article·2021-10

Daratumumab Immunopolymersome‐Enabled Safe and CD38‐Targeted Chemotherapy and Depletion of Multiple Myeloma

Na Yu, Yifan Zhang, Jiaying Li, Wenxing Gu, Shujing Yue, Bin Li, Fenghua Meng, Huanli Sun, Rainer Haag, Jiandong Yuan, Zhiyuan Zhong

Advanced Materials· Volume 33· Issue 39
Publisher page

Abstract

Abstract Multiple myeloma (MM) is a second ranking hematological malignancy. Despite the fast advancement of new treatments such as bortezormib and daratumumab, MM patients remain incurable and tend to eventually become relapsed and drug‐resistant. Development of novel therapies capable of depleting MM cells is strongly needed. Here, daratumumab immunopolymersomes carrying vincristine sulfate (Dar‐IPs‐VCR) are reported for safe and high‐efficacy CD38‐targeted chemotherapy and depletion of orthotopic MM in vivo. Dar‐IPs‐VCR made by postmodification via strain‐promoted click reaction holds tailored antibody density (2.2, 4.4 to 8.7 Dar per IPs), superb stability, small size (43–49 nm), efficacious VCR loading, and glutathione‐responsive VCR release. Dar4.4‐IPs‐VCR induces exceptional anti‐MM activity with an IC50 of 76 × 10−12 m to CD38‐positive LP‐1 MM cells, 12‐ and 20‐fold enhancement over nontargeted Ps‐VCR and free VCR controls, respectively. Intriguingly, mice bearing orthotopic LP‐1‐Luc MM following four cycles of i.v. administration of Dar4.4‐IPs‐VCR at 0.25 mg VCR equiv. kg−1 reveal complete depletion of LP‐1‐Luc cells, superior survival rate to all controls, and no body weight loss. The bone and histological analyses indicate bare bone and organ damage. Dar‐IPs‐VCR appears as a safe and targeted treatment for CD38‐overexpressed hematological malignancies.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Multiple Myeloma Research and Treatments · Peptidase Inhibition and Analysis · Cancer therapeutics and mechanisms

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Biomedical Polymers Laboratory College of Chemistry Chemical Engineering and Materials Science State Key Laboratory of Radiation Medicine and Protection Soochow University Suzhou 215123 P. R. China

Department of Orthopaedic Surgery Orthopaedic Institute The First Affiliated Hospital Soochow University Suzhou 215007 P. R. China

Department of Biology Chemistry and Pharmacy Institute for Chemistry and Biochemistry Freie Universität Berlin 14195 Berlin Germany

BrightGene Bio‐Medical Technology Co, Ltd Suzhou 215123 P. R. China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Jiangsu Province

References (69)

Show source-provided references
1. 10.1038/nrc.2016.10810.1038/nrc.2016.108 ↗
2. 10.1038/s41467-018-03705-y10.1038/s41467-018-03705-y ↗
3. 10.1038/nnano.2017.6910.1038/nnano.2017.69 ↗
4. 10.1038/s41551-019-0385-410.1038/s41551-019-0385-4 ↗
5. 10.1038/nrc90310.1038/nrc903 ↗
6. 10.1016/j.addr.2017.05.00610.1016/j.addr.2017.05.006 ↗
7. Mi P. · Adv. Mater. · 2020 · 32 · 29
8. 10.1038/nrd.2017.22710.1038/nrd.2017.227 ↗
9. 10.1016/S0140-6736(19)31774-X10.1016/S0140-6736(19)31774-X ↗
10. 10.1038/nrd.2016.26810.1038/nrd.2016.268 ↗
11. 10.1016/j.addr.2020.09.00310.1016/j.addr.2020.09.003 ↗
12. 10.1021/acs.accounts.9b0022810.1021/acs.accounts.9b00228 ↗
13. 10.1016/S1470-2045(12)70476-X10.1016/S1470-2045(12)70476-X ↗
14. 10.1038/s41416-018-0235-210.1038/s41416-018-0235-2 ↗
15. 10.1016/j.jconrel.2018.02.01510.1016/j.jconrel.2018.02.015 ↗
16. 10.1021/acsnano.9b0926310.1021/acsnano.9b09263 ↗
17. 10.1038/s41571-018-0018-y10.1038/s41571-018-0018-y ↗
18. 10.1001/jamaoncol.2018.212810.1001/jamaoncol.2018.2128 ↗
19. 10.1016/S1470-2045(14)70442-510.1016/S1470-2045(14)70442-5 ↗
20. 10.1016/S0140-6736(15)01226-X10.1016/S0140-6736(15)01226-X ↗
21. 10.1182/blood-2017-06-74094410.1182/blood-2017-06-740944 ↗
22. 10.1186/s13045-016-0283-010.1186/s13045-016-0283-0 ↗
23. 10.1158/1078-0432.CCR-16-086810.1158/1078-0432.CCR-16-0868 ↗
24. 10.1056/NEJMoa150634810.1056/NEJMoa1506348 ↗
25. 10.1016/S0140-6736(15)01120-410.1016/S0140-6736(15)01120-4 ↗
26. 10.1056/NEJMoa181724910.1056/NEJMoa1817249 ↗
27. 10.1016/S0140-6736(20)30734-010.1016/S0140-6736(20)30734-0 ↗
28. 10.1056/NEJMoa171467810.1056/NEJMoa1714678 ↗
29. 10.1002/cncr.3206510.1002/cncr.32065 ↗
30. 10.1016/S0140-6736(19)33018-110.1016/S0140-6736(19)33018-1 ↗
31. 10.3816/CLM.2003.s.00410.3816/CLM.2003.s.004 ↗
32. 10.1016/j.actbio.2020.06.02010.1016/j.actbio.2020.06.020 ↗
33. 10.1016/j.biomaterials.2011.04.02210.1016/j.biomaterials.2011.04.022 ↗
34. 10.1021/mp400547u10.1021/mp400547u ↗
35. 10.1016/j.biomaterials.2013.08.09110.1016/j.biomaterials.2013.08.091 ↗
36. 10.1007/s00280-012-2042-410.1007/s00280-012-2042-4 ↗
37. 10.1002/adma.20160006510.1002/adma.201600065 ↗
38. 10.1002/adma.20170328510.1002/adma.201703285 ↗
39. 10.1002/adma.20180031610.1002/adma.201800316 ↗
40. 10.1016/j.biomaterials.2019.11942010.1016/j.biomaterials.2019.119420 ↗
41. 10.1016/j.jconrel.2015.05.27110.1016/j.jconrel.2015.05.271 ↗
42. 10.1021/acs.molpharmaceut.6b0051910.1021/acs.molpharmaceut.6b00519 ↗
43. 10.1016/S2352-3026(19)30254-610.1016/S2352-3026(19)30254-6 ↗
44. 10.1158/1078-0432.CCR-18-159710.1158/1078-0432.CCR-18-1597 ↗
45. 10.1182/blood-2016-03-70343910.1182/blood-2016-03-703439 ↗
46. 10.1002/adma.20190474210.1002/adma.201904742 ↗
47. 10.1016/j.jconrel.2020.02.00410.1016/j.jconrel.2020.02.004 ↗
48. 10.1016/j.actbio.2018.09.02210.1016/j.actbio.2018.09.022 ↗
49. 10.1634/theoncologist.2015-039110.1634/theoncologist.2015-0391 ↗
50. 10.1016/S1040-8428(98)00023-710.1016/S1040-8428(98)00023-7 ↗
51. 10.1038/s41408-017-0045-410.1038/s41408-017-0045-4 ↗
52. 10.3390/cancers1208211310.3390/cancers12082113 ↗
53. 10.1002/adma.20160346310.1002/adma.201603463 ↗
54. 10.1073/pnas.140133711110.1073/pnas.1401337111 ↗
55. 10.1016/j.jconrel.2014.10.00510.1016/j.jconrel.2014.10.005 ↗
56. 10.1038/s41467-017-02758-910.1038/s41467-017-02758-9 ↗
57. 10.1016/j.jconrel.2017.11.04510.1016/j.jconrel.2017.11.045 ↗
58. 10.3390/cancers1102024810.3390/cancers11020248 ↗
59. 10.1016/S1470-2045(16)30206-610.1016/S1470-2045(16)30206-6 ↗
60. 10.1002/ajh.2579110.1002/ajh.25791 ↗
61. 10.3389/fonc.2019.0069910.3389/fonc.2019.00699 ↗
62. 10.1158/1078-0432.CCR-10-180410.1158/1078-0432.CCR-10-1804 ↗
63. 10.3389/fimmu.2017.0095410.3389/fimmu.2017.00954 ↗
64. 10.1101/cshperspect.a03128610.1101/cshperspect.a031286 ↗
65. 10.7150/thno.3020610.7150/thno.30206 ↗
66. 10.1182/blood-2018-10-87892610.1182/blood-2018-10-878926 ↗
67. 10.1002/ajh.2429110.1002/ajh.24291 ↗
68. 10.1038/leu.2015.1510.1038/leu.2015.15 ↗
69. 10.1038/nrneph.2018.810.1038/nrneph.2018.8 ↗